What's the patient satisfaction of subcutaneous #natalizumab in patients with relapsing-remitting #MultipleSclerosis?
Chiara Zecca and colleagues report the results from the real-world, multicenter Swiss SATYSFACTION study:
journals.sagepub.com/doi/full/10....
Chiara Zecca and colleagues report the results from the real-world, multicenter Swiss SATYSFACTION study:
journals.sagepub.com/doi/full/10....
September 29, 2026 at 10:15 AM
What's the patient satisfaction of subcutaneous #natalizumab in patients with relapsing-remitting #MultipleSclerosis?
Chiara Zecca and colleagues report the results from the real-world, multicenter Swiss SATYSFACTION study:
journals.sagepub.com/doi/full/10....
Chiara Zecca and colleagues report the results from the real-world, multicenter Swiss SATYSFACTION study:
journals.sagepub.com/doi/full/10....
More on subcutaneous #natalizumab for #MultipleSclerosis:
Final results from the SISTER study
journals.sagepub.com/doi/full/10....
Final results from the SISTER study
journals.sagepub.com/doi/full/10....
September 30, 2026 at 9:45 AM
More on subcutaneous #natalizumab for #MultipleSclerosis:
Final results from the SISTER study
journals.sagepub.com/doi/full/10....
Final results from the SISTER study
journals.sagepub.com/doi/full/10....
ANTITRUST
Biogen probed by Italy over MS drug competition
cinquewnews.blogspot.com/2026/05/biog... #Antitrust #Biogen #MultipleSclerosis #MSDrug #PharmaNews #ItalianAntitrust #CompetitionLaw #HealthcareIndustry #Biotech #Natalizumab #Sandoz #DrugMarket #EUCompetition #Pharmaceuticals #MedicalNews
Biogen probed by Italy over MS drug competition
cinquewnews.blogspot.com/2026/05/biog... #Antitrust #Biogen #MultipleSclerosis #MSDrug #PharmaNews #ItalianAntitrust #CompetitionLaw #HealthcareIndustry #Biotech #Natalizumab #Sandoz #DrugMarket #EUCompetition #Pharmaceuticals #MedicalNews
Biogen probed by Italy over MS drug competition
Italy probes Biogen over alleged attempts to block Sandoz’s MS biosimilar and limit competition in natalizumab drugs.
cinquewnews.blogspot.com
May 27, 2026 at 7:28 AM
ANTITRUST
Biogen probed by Italy over MS drug competition
cinquewnews.blogspot.com/2026/05/biog... #Antitrust #Biogen #MultipleSclerosis #MSDrug #PharmaNews #ItalianAntitrust #CompetitionLaw #HealthcareIndustry #Biotech #Natalizumab #Sandoz #DrugMarket #EUCompetition #Pharmaceuticals #MedicalNews
Biogen probed by Italy over MS drug competition
cinquewnews.blogspot.com/2026/05/biog... #Antitrust #Biogen #MultipleSclerosis #MSDrug #PharmaNews #ItalianAntitrust #CompetitionLaw #HealthcareIndustry #Biotech #Natalizumab #Sandoz #DrugMarket #EUCompetition #Pharmaceuticals #MedicalNews
El natalizumab es estupendo PERO si tienes el virus John Cunningham es peligroso. Pues bien el virus JC lo tiene un 70% de la población de la Tierra. Y ahora yo también.
April 2, 2024 at 3:15 PM
El natalizumab es estupendo PERO si tienes el virus John Cunningham es peligroso. Pues bien el virus JC lo tiene un 70% de la población de la Tierra. Y ahora yo también.
🧠 20 years of #natalizumab in #MultipleSclerosis care:
A new Review reflects on two decades of clinical experience with natalizumab—its efficacy, safety, and evolving role in treatment strategies.
📖 Read this Open Access article here: doi.org/10.1177/1756...
A new Review reflects on two decades of clinical experience with natalizumab—its efficacy, safety, and evolving role in treatment strategies.
📖 Read this Open Access article here: doi.org/10.1177/1756...
November 5, 2025 at 11:18 AM
🧠 20 years of #natalizumab in #MultipleSclerosis care:
A new Review reflects on two decades of clinical experience with natalizumab—its efficacy, safety, and evolving role in treatment strategies.
📖 Read this Open Access article here: doi.org/10.1177/1756...
A new Review reflects on two decades of clinical experience with natalizumab—its efficacy, safety, and evolving role in treatment strategies.
📖 Read this Open Access article here: doi.org/10.1177/1756...
Real-world evaluation of subcutaneous natalizumab in patients with highly active relapsing-remitting multiple sclerosis www.msard-journal.com/article/S221...
Real-world evaluation of subcutaneous natalizumab in patients with highly active relapsing-remitting multiple sclerosis
Multiple sclerosis (MS) is a chronic, immune-mediated disease characterized by inflammation,
demyelination, and neurodegeneration (McGinley et al., 2021; Mey et al., 2023). Natalizumab,
a recombinant ...
www.msard-journal.com
November 12, 2025 at 3:01 PM
Real-world evaluation of subcutaneous natalizumab in patients with highly active relapsing-remitting multiple sclerosis www.msard-journal.com/article/S221...
My #MS has now powered through 2 high efficacy, trusted DMTs, Natalizumab (Tysabri) and ofatumumab (Kesimpta).
Only next step is stem cell transplant according to my Neuro yesterday. Luckily I've got an appt next month. See of I can persuade them to deliver CAR-T instead 👍🏼
Only next step is stem cell transplant according to my Neuro yesterday. Luckily I've got an appt next month. See of I can persuade them to deliver CAR-T instead 👍🏼
April 15, 2026 at 11:20 AM
My #MS has now powered through 2 high efficacy, trusted DMTs, Natalizumab (Tysabri) and ofatumumab (Kesimpta).
Only next step is stem cell transplant according to my Neuro yesterday. Luckily I've got an appt next month. See of I can persuade them to deliver CAR-T instead 👍🏼
Only next step is stem cell transplant according to my Neuro yesterday. Luckily I've got an appt next month. See of I can persuade them to deliver CAR-T instead 👍🏼
Earlier this year, we interviewed Maya Zeineddine to hear about the differences between treatment with natalizumab and anti-CD20 monoclonal antibodies in #MultipleSclerosis.
Watch here:
👉 https://buff.ly/3ZAA42V
#MS #MultScler #ECTRIMS2024 #Neuroscience
Watch here:
👉 https://buff.ly/3ZAA42V
#MS #MultScler #ECTRIMS2024 #Neuroscience
Natalizumab versus anti-CD20 monoclonal antibodies in the treatment of MS - VJNeurology
Maya Zeineddine, PharmD, Lebanese American University, Byblos, Lebanon, discusses the differences between treatment with natalizumab and anti-CD20 monoclonal antibodies in...
buff.ly
December 13, 2024 at 2:00 PM
Earlier this year, we interviewed Maya Zeineddine to hear about the differences between treatment with natalizumab and anti-CD20 monoclonal antibodies in #MultipleSclerosis.
Watch here:
👉 https://buff.ly/3ZAA42V
#MS #MultScler #ECTRIMS2024 #Neuroscience
Watch here:
👉 https://buff.ly/3ZAA42V
#MS #MultScler #ECTRIMS2024 #Neuroscience
Tysabri is one of the most powerful MS therapies we have, & its mechanism is fascinating. It works by blocking immune cells from crossing into the brain & spinal cord, helping reduce inflammation. I broke this down in a short, clear video for anyone wanting to understand more!
youtu.be/6qTgl56EIaw
youtu.be/6qTgl56EIaw
How Does Tysabri (Natalizumab) Work for MS?
YouTube video by Dr. Rob Swanda
youtu.be
May 24, 2026 at 9:34 PM
Tysabri is one of the most powerful MS therapies we have, & its mechanism is fascinating. It works by blocking immune cells from crossing into the brain & spinal cord, helping reduce inflammation. I broke this down in a short, clear video for anyone wanting to understand more!
youtu.be/6qTgl56EIaw
youtu.be/6qTgl56EIaw
In a nationwide Danish comparative effectiveness study of RRMS, no significant differences were found between Ocrelizumab and Natalizumab regarding relapse rates, disability progression (PIRA), or MRI activity.
📚 Read now: onlinelibrary.wiley.com/doi/10.1111/...
@ean.org #WileyNeuro
#MS
📚 Read now: onlinelibrary.wiley.com/doi/10.1111/...
@ean.org #WileyNeuro
#MS
February 22, 2026 at 12:01 PM
In a nationwide Danish comparative effectiveness study of RRMS, no significant differences were found between Ocrelizumab and Natalizumab regarding relapse rates, disability progression (PIRA), or MRI activity.
📚 Read now: onlinelibrary.wiley.com/doi/10.1111/...
@ean.org #WileyNeuro
#MS
📚 Read now: onlinelibrary.wiley.com/doi/10.1111/...
@ean.org #WileyNeuro
#MS
This Retrospective cohort study (not a randomized trial) suggests ocrevus was slightly more effective at preventing MS disability progression. Ocrevus was linked to a 6% lower risk of moderate disability ( EDSS≥4) 95% CI: –11.28% to –0.46%; p=0.033) www.medrxiv.org/content/10.6...
Ocrelizumab versus Natalizumab in Relapsing-Remitting Multiple Sclerosis: A Registry-Linked Electronic Health Records Study
Background Ocrelizumab and natalizumab are commonly prescribed high-effectiveness disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS). However, no randomized clinical ...
www.medrxiv.org
December 19, 2025 at 7:31 AM
This Retrospective cohort study (not a randomized trial) suggests ocrevus was slightly more effective at preventing MS disability progression. Ocrevus was linked to a 6% lower risk of moderate disability ( EDSS≥4) 95% CI: –11.28% to –0.46%; p=0.033) www.medrxiv.org/content/10.6...
Proposed options for treatment of progressive multifocal leukoencephalopathy (PML) caused by tysabri: plasma exchange, Cytarabine, Topotecan, Mirtazapine, Mefloquine, Filgrastim, Pembrolizumab, Virus-Specific T Cells, IL-7, IL-2. pmc.ncbi.nlm.nih.gov/articles/PMC...
Natalizumab-associated progressive multifocal leukoencephalopathy
Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the brain resulting from infection of oligodendrocytes by JC virus (JCV) typically occurring in association with defects ...
pmc.ncbi.nlm.nih.gov
July 10, 2025 at 3:50 AM
Proposed options for treatment of progressive multifocal leukoencephalopathy (PML) caused by tysabri: plasma exchange, Cytarabine, Topotecan, Mirtazapine, Mefloquine, Filgrastim, Pembrolizumab, Virus-Specific T Cells, IL-7, IL-2. pmc.ncbi.nlm.nih.gov/articles/PMC...
Machine learning combined with high-content cell imaging enables accurate prediction of patient response to natalizumab, supporting more personalized and effective multiple sclerosis treatment strategies. doi.org/g942q6
Machine learning and cell imaging combine to predict effectiveness of multiple sclerosis medication
Brazilian researchers, in partnership with French institutions, have developed a tool that can predict how patients will respond to natalizumab, one of the most commonly used drugs for treating multiple sclerosis.
medicalxpress.com
September 25, 2025 at 6:29 PM
Machine learning combined with high-content cell imaging enables accurate prediction of patient response to natalizumab, supporting more personalized and effective multiple sclerosis treatment strategies. doi.org/g942q6
Are ocrelizumab and natalizumab equally effective in MS? A Danish study found no significant differences in disease control. However, the results should be interpreted with caution, as both patient groups had different characteristics.
onlinelibrary.wiley.com/doi/10.1111/...
#MS #neuroskyence
onlinelibrary.wiley.com/doi/10.1111/...
#MS #neuroskyence
February 23, 2026 at 1:18 PM
Are ocrelizumab and natalizumab equally effective in MS? A Danish study found no significant differences in disease control. However, the results should be interpreted with caution, as both patient groups had different characteristics.
onlinelibrary.wiley.com/doi/10.1111/...
#MS #neuroskyence
onlinelibrary.wiley.com/doi/10.1111/...
#MS #neuroskyence
Can you get PML as a side effect of tysabri/tyruko used for MS even with extended interval dosing (taking it less often than every 4 weeks)? Unfortunately, YES! This is a case series from Japan. pubmed.ncbi.nlm.nih.gov/40875960/
Natalizumab-Associated Progressive Multifocal Leukoencephalopathy After Natalizumab Extended Interval Dosing Therapy in Japan - PubMed
Given the high prevalence of JC virus antibody positivity in Japan, additional risk factors may contribute to NTZ-PML susceptibility. Although EID of natalizumab is expected to reduce PML risk, its ef...
pubmed.ncbi.nlm.nih.gov
August 29, 2025 at 5:57 PM
Can you get PML as a side effect of tysabri/tyruko used for MS even with extended interval dosing (taking it less often than every 4 weeks)? Unfortunately, YES! This is a case series from Japan. pubmed.ncbi.nlm.nih.gov/40875960/
es gibt Pharmaka, da könnte man meinen die sind nach Frauennamen benannt, wie Natalizumab oder Lenalidomid, aber das is nur Zufall crazy
June 24, 2026 at 10:30 AM
es gibt Pharmaka, da könnte man meinen die sind nach Frauennamen benannt, wie Natalizumab oder Lenalidomid, aber das is nur Zufall crazy
I do think those are different questions, and this framing doesn't really tell us anything useful.
"Oh you're making a lot of money, but you're spending all of it."
Well what that means depends on if it's on Rolexes and Porsches or natalizumab for your MS.
"Oh you're making a lot of money, but you're spending all of it."
Well what that means depends on if it's on Rolexes and Porsches or natalizumab for your MS.
February 26, 2025 at 4:33 PM
I do think those are different questions, and this framing doesn't really tell us anything useful.
"Oh you're making a lot of money, but you're spending all of it."
Well what that means depends on if it's on Rolexes and Porsches or natalizumab for your MS.
"Oh you're making a lot of money, but you're spending all of it."
Well what that means depends on if it's on Rolexes and Porsches or natalizumab for your MS.
Unbelievable to see our second @BrainBehavImm paper out in 2024🍾 @S_Proschinger @SergenBelen @maritschlagheck @TU_Dortmund and @SpohoKoeln 💪 Here we show that multimodal exercise training provokes Natalizumab-like effects in MS:
sciencedirect.com/science/articl…
sciencedirect.com/science/articl…
https://sciencedirect.com/science/articl…
December 14, 2024 at 2:37 PM
Unbelievable to see our second @BrainBehavImm paper out in 2024🍾 @S_Proschinger @SergenBelen @maritschlagheck @TU_Dortmund and @SpohoKoeln 💪 Here we show that multimodal exercise training provokes Natalizumab-like effects in MS:
sciencedirect.com/science/articl…
sciencedirect.com/science/articl…
New post: Natalizumab response and genetics https://multiple-sclerosis-research.org/2025/12/natalizumab-response-and-genetics/
December 15, 2025 at 10:32 AM
New post: Natalizumab response and genetics https://multiple-sclerosis-research.org/2025/12/natalizumab-response-and-genetics/
What a journey for people with MS and their HCPs. Natalizumab has taught us a great deal about MS. We try to tell the story in this review paper => buff.ly/WWjC7Ql
September 18, 2025 at 4:49 AM
What a journey for people with MS and their HCPs. Natalizumab has taught us a great deal about MS. We try to tell the story in this review paper => buff.ly/WWjC7Ql
New online!
Clara Grazia Chisari and colleagues compare STRATIFY JCV™ and IMMUNOWELL™ in detecting anti-JCV antibodies in patients receiving natalizumab for relapsing-remitting #MultipleSclerosis:
journals.sagepub.com/doi/full/10....
Clara Grazia Chisari and colleagues compare STRATIFY JCV™ and IMMUNOWELL™ in detecting anti-JCV antibodies in patients receiving natalizumab for relapsing-remitting #MultipleSclerosis:
journals.sagepub.com/doi/full/10....
Comparative evaluation of STRATIFY JCV™ and IMMUNOWELL™ assays for anti-JCV antibody detection in natalizumab-treated RRMS patients - Clara Grazia Chisari, Giulio Spampinato, Pina Crimì, Erika Ferraro...
Background: Two principal methods for detecting anti-John Cunningham virus (JCV) antibodies are currently utilized in clinical practice: STRATIFY JCV™, an ELISA...
journals.sagepub.com
December 15, 2025 at 2:29 PM
New online!
Clara Grazia Chisari and colleagues compare STRATIFY JCV™ and IMMUNOWELL™ in detecting anti-JCV antibodies in patients receiving natalizumab for relapsing-remitting #MultipleSclerosis:
journals.sagepub.com/doi/full/10....
Clara Grazia Chisari and colleagues compare STRATIFY JCV™ and IMMUNOWELL™ in detecting anti-JCV antibodies in patients receiving natalizumab for relapsing-remitting #MultipleSclerosis:
journals.sagepub.com/doi/full/10....
Approach to JCV testing with natalizumab biosimilar: a UK consensus statement www.msard-journal.com/article/S221...
Approach to JCV testing with natalizumab biosimilar: a UK consensus statement
Natalizumab is a highly effective treatment for multiple sclerosis. It is currently
used across the NHS for people with rapidly evolving severe (RES) MS. It has a shorter
therapeutic lag than other DM...
www.msard-journal.com
May 29, 2025 at 1:48 PM
Approach to JCV testing with natalizumab biosimilar: a UK consensus statement www.msard-journal.com/article/S221...
#MS_Selfie Q&A 81: Low JCV-index positive: should I switch to an anti-CD20 therapy or not?
Have any of you pwMS on natalizumab have similar concerns? How many of you have a low JCV index positive and have decided to stay on natalizumab? buff.ly/A3RS1Q0
Have any of you pwMS on natalizumab have similar concerns? How many of you have a low JCV index positive and have decided to stay on natalizumab? buff.ly/A3RS1Q0
March 19, 2025 at 8:41 AM
#MS_Selfie Q&A 81: Low JCV-index positive: should I switch to an anti-CD20 therapy or not?
Have any of you pwMS on natalizumab have similar concerns? How many of you have a low JCV index positive and have decided to stay on natalizumab? buff.ly/A3RS1Q0
Have any of you pwMS on natalizumab have similar concerns? How many of you have a low JCV index positive and have decided to stay on natalizumab? buff.ly/A3RS1Q0